Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
e.l.f. Beauty
ELF
|
$802M |
| 2 |
UnitedHealth
UNH
|
$418M |
| 3 |
AutoZone
AZO
|
$344M |
| 4 |
Kaspi.kz JSC
KSPI
|
$283M |
| 5 |
Enphase Energy
ENPH
|
$230M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$2.59B |
| 2 |
Spotify
SPOT
|
$1.68B |
| 3 |
Tesla
TSLA
|
$701M |
| 4 |
Teradyne
TER
|
$630M |
| 5 |
Shopify
SHOP
|
$406M |
Sector Composition
| 1 | Consumer Discretionary | 29.2% |
| 2 | Technology | 27.92% |
| 3 | Communication Services | 14.16% |
| 4 | Healthcare | 13.89% |
| 5 | Financials | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
CRISPR Therapeutics
CRSP
$4.8B
| $21.9M | 0.02% |
405,425
+9,510
| +2% | +$514K |
|
177
Booking.com
BKNG
$181B
| $21.9M | 0.02% |
5,524
+1,675
| +44% | +$6.64M |
|
178
RxSight
RXST
$347M
| $21.6M | 0.02% |
358,215
+291,733
| +439% | +$17.6M |
|
179
KE Holdings
BEKE
$21.9B
| $20.4M | 0.02% |
1,444,247
-19,381
| -1% | -$274K |
|
180
Rexford Industrial Realty
REXR
$9.96B
| $20.3M | 0.02% |
454,763
-142,292
| -24% | -$6.34M |
|
181
BlackLine
BL
$3.28B
| $20M | 0.02% |
412,483
-195,982
| -32% | -$9.5M |
|
182
Burford Capital
BUR
$2.91B
| $19.8M | 0.02% |
1,534,668
+207,157
| +16% | +$2.67M |
|
183
Ares Capital
ARCC
$15.8B
| $19M | 0.01% |
913,639
-270,010
| -23% | -$5.63M |
|
184
Clear Secure
YOU
$3.41B
| $18.7M | 0.01% |
1,000,000
| – | – |
|
185
Aehr Test Systems
AEHR
$786M
| $18.7M | 0.01% |
1,670,590
+841,964
| +102% | +$9.4M |
|
186
Digimarc
DMRC
$175M
| $18.6M | 0.01% |
598,322
-122,505
| -17% | -$3.8M |
|
187
Ambarella
AMBA
$3.44B
| $17.6M | 0.01% |
326,236
-176,643
| -35% | -$9.53M |
|
188
Brookfield
BN
$99.6B
| $16.8M | 0.01% |
404,949
| – | – |
|
189
Carlisle Companies
CSL
$16.8B
| $16.8M | 0.01% |
41,349
-2,746
| -6% | -$1.11M |
|
190
Trupanion
TRUP
$1.92B
| $16.6M | 0.01% |
565,800
-130,450
| -19% | -$3.84M |
|
191
Progressive
PGR
$146B
| $16M | 0.01% |
77,056
| – | – |
|
192
Brookfield Renewable
BEPC
$6.04B
| $15M | 0.01% |
529,766
-248,864
| -32% | -$7.06M |
|
|
ADAP
193
Adaptimmune Therapeutics
ADAP
$13.5M
| $14.8M | 0.01% |
15,149,203
-722,672
| -5% | -$705K |
|
194
Beam Therapeutics
BEAM
$1.88B
| $14.6M | 0.01% |
623,640
-128,754
| -17% | -$3.02M |
|
|
NBTX
195
Nanobiotix
NBTX
$411M
| $14.3M | 0.01% |
2,869,030
| – | – |
|
196
Waters Corp
WAT
$17.8B
| $14M | 0.01% |
48,249
-2,385
| -5% | -$692K |
|
197
Charles River Laboratories
CRL
$7.99B
| $14M | 0.01% |
67,537
+3
| +0% | +$620 |
|
198
TJX Companies
TJX
$157B
| $13.9M | 0.01% |
126,549
| – | – |
|
199
Confluent
CFLT
$6.4B
| $13.2M | 0.01% |
447,958
+4,283
| +1% | +$126K |
|
200
Oscar Health
OSCR
$4.75B
| $13M | 0.01% |
822,088
| – | – |
|